Sanofi has announced the completion of its acquisition of Vigil Neuroscience, Inc., a move that enhances its neurology pipeline with the addition of VG-3927, a promising oral, small-molecule TREM2 agonist. This acquisition, valued at approximately $470 million, allows Sanofi to advance its research in Alzheimer's disease and other neurodegenerative conditions. Shareholders of Vigil Neuroscience will also receive a contingent value right, entitling them to a deferred cash payment upon VG-3927's first commercial sale. Notably, VGL101, Vigil's second clinical program, was not part of this acquisition. Sanofi has stated that this transaction will not impact its 2025 financial guidance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001121544-en) on August 06, 2025, and is solely responsible for the information contained therein.